Revenue + Forward P/E
West Pharmaceutical Services, Inc. (WST) quarterly revenue and forward P/EForward P/E: 38.1x
RevenueRevenue (est)Forward P/E
Fair value & valuation models
Fair value models are a Plus feature
Upgrade to Plus for the interactive DCF model, valuation bands, and implied-price scenarios.
71% OFF$23.99 $6.99/mo
Ends in23:59:59
Cancel anytime. Secure checkout via Stripe.
Valuation
Market cap
$24.47B
Enterprise value
$23.67B
P/E ratio (TTM)
42.79x
P/S ratio (TTM)
7.15x
P/B ratio
7.97x
EV/Sales
7.12x
EV/EBITDA
28.72x
Dividend yield
0.26%
Income statement (TTM)
Revenue (TTM)
$3.07B
Gross profit (TTM)
$1.10B
Operating income (TTM)
$617.40M
EBITDA (TTM)
$723.60M
Net income (TTM)
$493.70M
Free cash flow (TTM)
$468.90M
Margins & returns
Gross margin
36.77%
Operating margin
20.64%
Profit margin
16.98%
Return on equity
18.51%
Return on assets
13.86%
Per-share metrics
EPS (TTM)
$7.98
Dividend yield
0.26%
Beta
1.16
Capital structure
Cash & equivalents
$791.30M
Total debt
$416.70M
Net debt
$-374.60M
Shares outstanding
70.38M
Financial health
Current ratio
3.02
Debt / equity
0.13
Debt / assets
0.10
Interest coverage
1029.00
| Company | Market cap | P/E | P/S | EV/EBITDA | Div yield |
|---|---|---|---|---|---|
| $1.15T | 42.41x | 15.59x | 34.80x | 0.54% | |
| $629.91B | 30.45x | 6.47x | 20.76x | 1.99% | |
| $443.10B | 127.13x | 7.29x | 30.82x | 2.63% | |
| $365.06B | 27.06x | 0.85x | 16.46x | 2.13% | |
| $354.73B | 23.91x | 4.80x | 15.14x | 2.67% | |
| $332.91B | 36.82x | 4.94x | 19.57x | 2.56% | |
| $24.47B | 42.79x | 7.15x | 28.72x | 0.26% |